References
- Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 1975: 6(Nov): 307–16
- Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977: 62(5): 707–14
- Tall AR, Small DA. Plasma high-density lipoproteins. N Engl J Med 1978: 299(22): 1232–6
- Fredrickson DS. An international Classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 1971: 75(3): 471–2
- Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983: 308(15): 862–7
- Hartung GH, Foreyt JP, Mitchell RE, et al. Relationship of diet to high-density lipoprotein cholesterol in middle-aged marathon runnere, Joggers, and inactive men. N Engl J Med 1980: 302(7): 357–61
- Hartung GH, Foreyt JP, Mitchell RE, et al. Effect of alcohol intake on high-density lipoprotein cholesterol levels in runnere and inactive men. JAMA 1983: 249(6): 747–50
- Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease: the cooperative lipoprotein phenotyping study. Circulation 1977: 55(5): 767–72
- Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983: 67(4): 730–4
- Stamler J, Epstein FH. Coronary heart disease: risk factors as guides to preventive action. Pre Med 1972: 1(1): 27–48
- Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976: 37(2): 269–82
- Keys A, et al. Coronary heart disease in seven countries. Circulation 1970: 41(4 Suppl 1)
- American Druggist blue book. Lee FH, ed. New York: Hearst Corporation. 1984
- Heel RC, Brogden RN, Pakes GE, et al. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolemia. Drugs 1980: 19(3): 161–80
- Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975: 231(4): 360–81
- Riesen WF, Keller M, Mordasini R. Probucol in hypercholesterolemia: a double blind study. Atherosclerosis 1980: 36(2): 201–7
- Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using Clofibrate. Br Heart J 1978: 40: 1069–118
- Nye ER, Sutherland WH, Temple WA. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and Clofibrate. NZ Med J 1980: 92(671): 345–9
- Mabuchi H, Haba T, Tatami R, et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 1981: 305(9): 478–82
- Mabuchi H, Sakai T, Sakai Y, et al. Reduction of serum cholesterol in heterozygous patients with famillal hypercholesterolemia: additive effects of compactin and cholestyramine. N Engl J Med 1983: 308(11): 609–13
- Buchwald H, Moore RB, Varco RL. Surgical treatment of hyperlipidemia. Circulation 1974: 49(5 Suppl 1): 1–37
- Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease. JAMA 1984: 251(3): 351–64
- Glueck CJ. Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis Ann Intern Med 1982: 96(4): 475–82
- Barndt R Jr, Blankenhorn DH, Crawford DW et al. Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Intern Med 1977: 86(2): 13–46
- Wissler RW, Vesselinovitch D. Studies in regression of advanced atherosclerosis in experimental animals and man. Ann NY Acad Sci 1976: 275(Aug): 363–78
- Fuchs R, Scheidt SS. Prevention of coronary atherosclerosis. Cardiovasc Rev Rpt 1983: 4(May): 671–95: 4(Jun): 791–812
- Malinow MR. Regression of atherosclerosis in humans: a new frontier? Postgrad Med 1983: 73(5): 232–42